GHRP-6

Mechanism

GHRP-6 is a GHS-R1a agonist — the same ghrelin receptor that ipamorelin targets — but with significantly broader receptor promiscuity. Where ipamorelin is selective for the GH axis, GHRP-6 also activates ghrelin-mediated appetite signaling in the hypothalamus and produces modest elevations in cortisol and prolactin. The appetite drive is not a side effect to ignore: it's a direct consequence of the ghrelin pathway activation, and at typical doses it produces a noticeable and persistent hunger window following each injection.

The GH pulse magnitude from GHRP-6 is slightly larger than an equivalent ipamorelin dose, which is part of why bulking-phase users prefer it. The cortisol and prolactin elevation is modest at standard doses (100 mcg) and unlikely to cause meaningful negative effects on short cycles, but it accumulates on long ones — which is why GHRP-6 runs shorter cycles than ipamorelin as a rule. Like all GHRPs, it synergizes substantially with a GHRH (CJC-1295 DAC or sermorelin), which raises the pituitary's output ceiling for each triggered pulse.

The appetite effect is the key differentiator that drives peptide selection. Users in a caloric surplus who struggle to hit protein and calorie targets find GHRP-6 a practical tool. Users in a deficit who already manage hunger carefully will find it works against them. This is a tool for bulking phases by design; ipamorelin is the cut-phase swap.

Typical protocol

• Starter: 100 mcg SC 2×/day (fasted AM + pre-bed).
• Advanced: 100 mcg SC 3×/day (fasted AM, pre-workout, pre-bed). Paired with a GHRH (CJC-1295 DAC or sermorelin) at each dose.
• Cycle length: 8–10 weeks on / 4 weeks off. The cortisol and prolactin burden limits run length — shorter cycles than ipamorelin.
• Reconstitution: 5 mg vial + 2.5 mL BAC water → 2 mg/mL. 5 IU on a U-100 insulin syringe = 0.05 mL = 100 mcg.

Who it's for

Muscle growth, specifically users in a caloric surplus who want the GH-pulse benefit combined with appetite drive. Recovery is secondary. The GHRP-6 appetite window can functionally help users reach aggressive caloric targets during bulk phases. Cut-phase users should default to ipamorelin instead unless they have strict enough meal planning to absorb the hunger without deviation.

Stacks well with

• cjc 1295 dac 2mg — mandatory GHRH pairing (once-weekly). Raises the pulse ceiling for each GHRP-6 trigger.
• sermorelin 2mg — short-acting GHRH alternative for users who prefer nightly pulse-only dosing.

Watch-outs

• Significant appetite drive 20–40 minutes after each injection. Do not use during a cut unless meal plans are rigid and pre-planned around the hunger window.
• Cortisol and prolactin elevation is real. Mandatory cycle breaks at 8–10 weeks — do not run past this without a full 4-week off period.
• Do not combine with ipamorelin at the same injection timing. They compete for the same receptor; the second compound adds minimal GH output while the cortisol burden from GHRP-6 is fully expressed. If using both in one day, space them by several hours or simply pick one GHRP per cycle.